SCHEMBL3367727

SCHEMBL3367727

COc1cc(-c2cc(B3OCC(C)(C)CO3)cn2S(=O)(=O)c2ccc(C)cc2)cc(OC)c1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.37
▸ MAPT P10636 5/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ MEN1 O00255 5/20 0.34
▸ LMNA P02545 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ APOBEC3G Q9HC16 1/20 0.34
▸ POLB P06746 2/20 0.34
▸ ACVR1 Q04771 1/20 0.34
▸ TUBB4A P04350 2/20 0.32
▸ TUBB P07437 2/20 0.32
▸ TUBA3C P0DPH7 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3368168 0.92 L3MBTL1 (0.38) KMT2AMAPTALDH1A1TDP1KDM4E
SCHEMBL3367690 0.76 CA1 (0.43) KMT2AMAPTALDH1A1SMN1; SMN2TDP1
SCHEMBL3368043 0.74 TUBB4A (0.44) KMT2AMAPTALDH1A1SMN1; SMN2TDP1
SCHEMBL1376420 0.72 CA2 (0.61) KMT2AMAPTALDH1A1KDM4ECA12
SCHEMBL1379606 0.71 MAP3K11 (0.48) KMT2AALDH1A1L3MBTL1CA12CA1
SCHEMBL2191679 0.69 CYP2C9 (0.36) KMT2AMAPTALDH1A1KDM4EL3MBTL1
SCHEMBL1376476 0.68 MAP3K11 (0.42) KMT2AMAPTALDH1A1MEN1LMNA
SCHEMBL3371555 0.67 CA12 (0.43) KMT2AMAPTALDH1A1KDM4EL3MBTL1
SCHEMBL1379771 0.67 MAPT (0.37) KMT2AMAPTALDH1A1SMN1; SMN2TDP1
SCHEMBL1377862 0.66 MAPT (0.53) KMT2AMAPTALDH1A1SMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1628957-B1 SULFOPYRROLES TAKEDA PHARMACEUTICAL (JP) 2010-09-29 — — EP disclosed
US-7612064-B2 Sulfopyrroles TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-03 — — US disclosed
US-20070060570-A1 Sulfopyrroles TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-15 — — US disclosed
EP-1628957-A1 SULFOPYRROLES Takeda Pharmaceutical Company Limited (JP) 2006-03-01 — — EP disclosed
WO-2004103968-A1 SULFOPYRROLES APONETICS AG (CH) 2004-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060570-A1 Sulfopyrroles TYK2, ARSA, SULT2A1 KMT2A 2214/4885MAPT 4766/4885ALDH1A1 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback